In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019

Zelalem Temesgen; Saad S. Kenderian; Andrew D. Badley

doi:10.1016/j.mayocp.2020.12.029

In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019

Zelalem Temesgen, Saad S. Kenderian, Andrew D. Badley

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	817-818
Number of pages	2
Journal	Mayo Clinic proceedings
Volume	96
Issue number	3
DOIs	https://doi.org/10.1016/j.mayocp.2020.12.029
State	Published - Mar 2021

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2020.12.029

Cite this

@article{1eda056355e343a9ae0deb276c4014da,

title = "In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019",

author = "Zelalem Temesgen and Kenderian, {Saad S.} and Badley, {Andrew D.}",

year = "2021",

month = mar,

doi = "10.1016/j.mayocp.2020.12.029",

language = "English (US)",

volume = "96",

pages = "817--818",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "3",

}

TY - JOUR

T1 - In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019

AU - Temesgen, Zelalem

AU - Kenderian, Saad S.

AU - Badley, Andrew D.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85101753014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101753014&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2020.12.029

DO - 10.1016/j.mayocp.2020.12.029

M3 - Letter

C2 - 33673930

AN - SCOPUS:85101753014

SN - 0025-6196

VL - 96

SP - 817

EP - 818

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 3

ER -

In Reply — Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this